First Allied Advisory Services’s GSK GSK Stock Holding History

First Allied Advisory Services’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1.61M	Sell	34,160 -2,366	-6%	-$119K	0.05%	344
2020 Q2	$1.86M	Buy	36,526 +1,052	+3%	+$54K	0.07%	298
2020 Q1	$1.68M	Sell	35,474 -4,460	-11%	-$238K	0.07%	279
2019 Q4	$2.35M	Buy	39,934 +3,037	+8%	+$169K	0.08%	281
2019 Q3	$1.98M	Sell	36,897 -1,701	-4%	-$87.5K	0.07%	304
2019 Q2	$1.93M	Sell	38,598 -556	-1%	-$27.9K	0.07%	314
2019 Q1	$2.04M	Sell	39,154 -2,032	-5%	-$102K	0.07%	292
2018 Q4	$1.97M	Sell	41,186 -315	-0.8%	-$15.5K	0.08%	273
2018 Q3	$2.08M	Buy	41,501 +3,282	+9%	+$167K	0.07%	289
2018 Q2	$1.92M	Sell	38,219 -4,753	-11%	-$239K	0.07%	296
2018 Q1	$2.1M	Buy	42,972 +554	+1%	+$25.8K	0.08%	268
2017 Q4	$1.88M	Sell	42,418 -101,324	-70%	-$4.68M	0.07%	286
2017 Q3	$7.34M	Buy	143,742 +94,957	+195%	+$4.82M	0.32%	69
2017 Q2	$2.63M	Sell	48,785 -3,491	-7%	-$186K	0.12%	197
2017 Q1	$2.75M	Sell	52,276 -55	-0.1%	-$2.79K	0.14%	158
2016 Q4	$2.52M	Buy	52,331 +8,203	+19%	+$405K	0.13%	183
2016 Q3	$2.38M	Sell	44,128 -6,346	-13%	-$348K	0.13%	190
2016 Q2	$2.74M	Buy	50,474 +6,921	+16%	+$365K	0.15%	156
2016 Q1	$2.2M	Sell	43,553 -1,211	-3%	-$60.3K	0.12%	189
2015 Q4	$2.26M	Sell	44,764 -1,298	-3%	-$66.2K	0.12%	199
2015 Q3	$2.22M	Sell	46,062 -362	-0.8%	-$18.8K	0.12%	192
2015 Q2	$2.4M	Buy	46,424 +6,741	+17%	+$380K	0.11%	223
2015 Q1	$2.3M	Buy	39,683 +9,436	+31%	+$541K	0.15%	171
2014 Q4	$1.62M	Buy	30,247 +4,421	+17%	+$247K	0.12%	210
2014 Q3	$1.49M	Buy	25,826 +10,402	+67%	+$638K	0.12%	203
2014 Q2	$1.03M	Sell	15,424 -1,267	-8%	-$85.8K	0.08%	306
2014 Q1	$1.12M	Sell	16,691 -1,646	-9%	-$111K	0.08%	273
2013 Q4	$1.23M	Sell	18,337 -42,707	-70%	-$2.77M	0.1%	241
2013 Q3	$3.83M	Buy	61,044 +45,446	+291%	+$2.93M	0.22%	119
2013 Q2	$975K	Buy	+15,598	New	+$990K	0.08%	269

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

First Allied Advisory Services's GSK Position: Q3 2020 in Review

First Allied Advisory Services reduced its GSK (GSK) stake by 6.5% in Q3 2020, selling an estimated $119K and leaving 34,160 shares worth $1.61M. The position accounts for 0.05% of the portfolio, ranked #344.

First Allied Advisory Services first reported a position in GSK in Q2 2013 and has held it in 30 quarters since. The position peaked at $7.34M in Q3 2017. 826 funds tracked by Wall St. Rank hold GSK as of Q3 2020.

First Allied Advisory Services held 34,160 shares of GSK worth $1.61M as of Q3 2020.
First Allied Advisory Services sold 2,366 GSK shares in Q3 2020, an estimated $119K.
GSK made up 0.05% of First Allied Advisory Services's portfolio in Q3 2020, its #344 holding.
First Allied Advisory Services first reported a position in GSK in Q2 2013 and has held it in 30 quarters since.
First Allied Advisory Services's GSK position peaked at $7.34M in Q3 2017.
826 funds tracked by Wall St. Rank held GSK as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.